A Phase 2 interventional study of Alirocumab and Placebo in Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-06-17.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 39th largest by enrollment, is one of 12 that started in 2012, is one of 9 in phase 2, and was the 11th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 12 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
13 studies in Hypercholesterolemia by Regeneron Pharmaceuticals: none open now, 1 under way, none of them phase 3. Of 12 finished, 10 (83%) have results posted.
Among the 13 studies in Hypercholesterolemia by Regeneron Pharmaceuticals, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2012, is one of 5 in phase 2, and was the 4th registered.
Regeneron Pharmaceuticals’s Hypercholesterolemia studies by the year they started, since 2010.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Regeneron Pharmaceuticals’s 13 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to assess the pharmacodynamic (PD) effect of alirocumab on serum low density lipoprotein cholesterol (LDL-C) during 14 weeks of subcutaneous (SC) administered alirocumab in patients with autosomal dominant hypercholesterolemia (ADH) and gain-of-function mutation (GOFm) in 1 or both alleles of the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or with loss-of-function mutation (LOFm) in 1 or more alleles of the apolipoprotein (ApoB) gene.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion criteria include, but are not limited to the following:
Exclusion Criteria:
Exclusion criteria include, but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (Cohort 1): Alirocumab 150 mg subcutaneous (SC) injection at Week 0 (Day 1), Week 2 (Day 15), Week 4, 6 and 10 (matching placebo at Week 8, 12 and 14) during the double-blind period (Group A). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
Drug: Alirocumab · Drug: Placebo
Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (Cohort 1): Alirocumab 150 mg subcutaneous (SC) injection at Week 2 (Day 15), Week 4, 6, 8 and 12 (\[matching placebo at Week 0 (Day 1), 10 and 14\]) during the double-blind period (Group B). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
Drug: Alirocumab · Drug: Placebo
Participants with gain-of-function mutation (GOFm) in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or loss-of-function mutation (LOFm) in the apolipoprotein (Apo) B gene (Cohort 2): Alirocumab 150 mg subcutaneous (SC) injection at Week 0 (Day 1), Week 2 (Day 15), Week 4, 6 and 10 (matching placebo at Week 8, 12 and 14) during the double-blind period (Group C). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
Drug: Alirocumab · Drug: Placebo
Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or loss-of-function mutation (LOFm) in apolipoprotein (Apo) B gene (Cohort 2): Alirocumab 150 mg subcutaneous (SC) injection at Week 2 (Day 15), Week 4, 6, 8 and 12 (\[matching placebo at Week 0 (Day 1), 10 and 14\]) during the double-blind period (Group D). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
Drug: Alirocumab · Drug: Placebo
SC injection in the abdomen
Also known as: Praluent®, REGN727, SAR236553
SC injection in the abdomen
Percent Change in Measured Serum Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 15
By day 15, participants in groups A and C had received 1 subcutaneous (SC) dose of 150 mg alirocumab and participants in group B and D had received 1 SC dose of placebo. \[Baseline adjusted least squares (LS) means and standard errors were obtained using analysis of covariance (ANCOVA) model specifying the treatment arm as the fixed effect and the baseline measured LDL-C value as a covariate.\]
Time frame: Baseline to Day 15
Percent Change in Apolipoprotein (Apo) B100 From Baseline to Day 15
Baseline adjusted LS means and standard errors were obtained using the same ANCOVA model as for primary endpoint specifying the treatment arm as the fixed effect and the parameter value as a covariate.
Time frame: Baseline to Day 15
Percent Change in Non High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Day 15
Time frame: Baseline to Day 15
Percent Change in Total Cholesterol (Total-C) From Baseline to Day 15
Time frame: Baseline to Day 15
Percent Change in Apolipoprotein (Apo) B100/ ApoA-1 Ratio From Baseline to Day 15
Time frame: Baseline to Day 15
This study was conducted at 4 sites, 3 in France \& 1 in the United States. Twenty-eight participants were screened between Feb 2012 \& Apr 2013. A total of 23 participants were enrolled: 13 in cohort 1 \& 10 in cohort 2. Recruitment for cohort 2 occurred after the un-blinding of cohort 1 \& analyses of the double-blind study data for cohort 1.
| Milestone | PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) | PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) | PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) | PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) | PCSK9 GOFm (Cohort 1: Group A and Group B) | PCSK9 GOFm/ApoB LOFm (Cohort 2: Group C and Group D) |
|---|---|---|---|---|---|---|
| Started | 6 | 7 | 5 | 5 | 0 | 0 |
| Completed db period (day 99) | 6 | 7 | 5 | 5 | 0 | 0 |
| Completed db follow-up (day 155) | 6 | 7 | 5 | 5 | 0 | 0 |
| Completed | 6 | 7 | 5 | 5 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) | PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) | PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) | PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) | PCSK9 GOFm (Cohort 1: Group A and Group B) | PCSK9 GOFm/ApoB LOFm (Cohort 2: Group C and Group D) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 13 | 10 |
| Started open-label extension period | 0 | 0 | 0 | 0 | 11 | 10 |
| Completed study | 0 | 0 | 0 | 0 | 10 | 10 |
| Completed | 0 | 0 | 0 | 0 | 10 | 10 |
| Not completed | 0 | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Chose not to enter ole period | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Refused to come into office | 0 | 0 | 0 | 0 | 1 | 0 |
By day 15, participants in groups A and C had received 1 subcutaneous (SC) dose of 150 mg alirocumab and participants in group B and D had received 1 SC dose of placebo. \[Baseline adjusted least squares (LS) means and standard errors were obtained using analysis of covariance (ANCOVA) model specifying the treatment arm as the fixed effect and the baseline measured LDL-C value as a covariate.\]
| percent change | PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) | PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) | PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) | PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) |
|---|---|---|---|---|
| Percent Change in Measured Serum Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 15 | -62.48 ± 8.217 | -8.77 ± 7.575 | -48.21 ± 7.660 | -4.93 ± 7.660 |
Baseline adjusted LS means and standard errors were obtained using the same ANCOVA model as for primary endpoint specifying the treatment arm as the fixed effect and the parameter value as a covariate.
| percent change | PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) | PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) | PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) | PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) |
|---|---|---|---|---|
| Percent Change in Apolipoprotein (Apo) B100 From Baseline to Day 15 | -53.33 ± 8.678 | -3.78 ± 8.008 | -47.73 ± 7.547 | -3.09 ± 7.547 |
| percent change | PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) | PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) | PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) | PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) |
|---|---|---|---|---|
| Percent Change in Non High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Day 15 | -56.87 ± 8.217 | -7.50 ± 7.575 | -44.40 ± 7.357 | -4.04 ± 7.357 |
| percent change | PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) | PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) | PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) | PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) |
|---|---|---|---|---|
| Percent Change in Total Cholesterol (Total-C) From Baseline to Day 15 | -36.94 ± 5.203 | -6.18 ± 4.802 | -29.40 ± 4.422 | -7.18 ± 4.422 |
| percent change | PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) | PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) | PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) | PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) |
|---|---|---|---|---|
| Percent Change in Apolipoprotein (Apo) B100/ ApoA-1 Ratio From Baseline to Day 15 | -55.26 ± 7.188 | -5.53 ± 6.647 | -48.34 ± 8.090 | 0.99 ± 8.090 |
Collected over From the screening visit after the last alirocumab injection in the open-label period + 70 days through the end of study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2:Group D) | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| OLE Period: PCSK9 GOFm (Cohort 1) Group A & Group B | 0/11 (0%) | 3/11 (27.3%) | 10/11 (90.9%) |
| OLE Period: PCSK9 GOFm/ ApoB LOFm (Cohort 2) Group C & Group D | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| Event | PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) | PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) | PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) | PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2:Group D) | OLE Period: PCSK9 GOFm (Cohort 1) Group A & Group B | OLE Period: PCSK9 GOFm/ ApoB LOFm (Cohort 2) Group C & Group D |
|---|---|---|---|---|---|---|
| Chest painGeneral disorders | 1/6 | 0/7 | 0/5 | 0/5 | 1/11 | 0/10 |
| Angina unstableCardiac disorders | 0/6 | 0/7 | 0/5 | 0/5 | 1/11 | 0/10 |
| Myocardial ischaemiaCardiac disorders | 0/6 | 0/7 | 0/5 | 0/5 | 1/11 | 0/10 |
| Salivary gland disorderGastrointestinal disorders | 0/6 | 0/7 | 0/5 | 0/5 | 1/11 | 0/10 |
| ObesityMetabolism and nutrition disorders | 0/6 | 0/7 | 0/5 | 0/5 | 1/11 | 0/10 |
| Event | PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) | PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) | PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) | PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2:Group D) | OLE Period: PCSK9 GOFm (Cohort 1) Group A & Group B | OLE Period: PCSK9 GOFm/ ApoB LOFm (Cohort 2) Group C & Group D |
|---|---|---|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 2/6 | 1/7 | 2/5 | 1/5 | 4/11 | 2/10 |
| GastroenteritisInfections and infestations | 2/6 | 1/7 | 1/5 | 0/5 | 0/11 | 1/10 |
| HeadacheNervous system disorders | 0/6 | 2/7 | 0/5 | 1/5 | 0/11 | 0/10 |
| VertigoEar and labyrinth disorders | 0/6 | 0/7 | 0/5 | 1/5 | 0/11 | 1/10 |
| Abdominal discomfortGastrointestinal disorders | 1/6 | 0/7 | 0/5 | 1/5 | 0/11 | 0/10 |
| Abdominal distensionGastrointestinal disorders | 0/6 | 0/7 | 0/5 | 1/5 | 0/11 | 0/10 |
| Chest painGeneral disorders | 1/6 | 0/7 | 0/5 | 1/5 | 1/11 | 0/10 |
| Herpes zosterInfections and infestations | 0/6 | 0/7 | 0/5 | 1/5 | 0/11 | 0/10 |
| InfluenzaInfections and infestations | 0/6 | 0/7 | 1/5 | 0/5 | 0/11 | 0/10 |
| Lower respiratory tract infectionInfections and infestations | 1/6 | 0/7 | 1/5 | 1/5 | 0/11 | 1/10 |
| Age, Continuous(years) | PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) | PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) | PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) | PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) | Total |
|---|---|---|---|---|---|
| Mean | 42.3 ± 14.72 | 46.4 ± 13.24 | 45.6 ± 3.21 | 42.0 ± 10.84 | 44.2 ± 11.15 |
| Age, Customized(Participants) | PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) | PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) | PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) | PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) | Total |
|---|---|---|---|---|---|
| In utero | 0 | 0 | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 | 0 | 0 |
| Adults (18-64 years) | 6 | 7 | 5 | 5 | 23 |
| From 65-84 years | 0 | 0 | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) | PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) | PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) | PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) | Total |
|---|---|---|---|---|---|
| Female | 4 | 5 | 4 | 2 | 15 |
| Male | 2 | 2 | 1 | 3 | 8 |
| Ethnicity (NIH/OMB)(Participants) | PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) | PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) | PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) | PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 7 | 5 | 5 | 23 |
| Race (NIH/OMB)(Participants) | PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) | PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) | PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) | PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) | Total |
|---|---|---|---|---|---|
| White | 5 | 6 | 5 | 5 | 21 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Other: Indian Ocean Islander | 0 | 1 | 0 | 0 | 1 |
| Other: Mauritius | 1 | 0 | 0 | 0 | 1 |
| Measured Low-Density Lipoprotein Cholesterol (LDL-C)(milligrams per deciliter (mg/dL)) | PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) | PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) | PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) | PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) | Total |
|---|---|---|---|---|---|
| Mean | 108.8 ± 33.84 | 144.3 ± 68.39 | 187.4 ± 98.12 | 151.0 ± 82.70 | 145.9 ± 72.82 |
| Total Cholesterol(mg/dL) | PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) | PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) | PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) | PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) | Total |
|---|---|---|---|---|---|
| Mean | 181.3 ± 41.89 | 216.3 ± 78.61 | 249.8 ± 86.68 | 226.0 ± 77.80 | 216.6 ± 71.84 |
| Non-high-density lipoprotein cholesterol (Non-HDL-C)(mg/dL) | PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) | PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) | PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) | PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) | Total |
|---|---|---|---|---|---|
| Mean | 124.3 ± 49.00 | 165.9 ± 75.59 | 189.4 ± 93.43 | 163.4 ± 86.88 | 159.6 ± 74.97 |
2 further baseline measures are reported on the registry.
Ran from Feb 2012 to primary completion in Jun 2014, 27 months.
Results were first posted in Jun 2020, 6 years after primary completion. A results delay was requested in Jan 2015.
Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 27 months is above that.
Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab